Impact of empiric antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) infection and associated Clostridioides difficile infection (CDI) risk: Secondary analysis of the CLEAR trial. (16th December 2021)

• Record Type: Journal Article
• Authors: Weiland, Anastasiia S.; Lu, Julia Y.; Chen, Caleb S.; Tjoa, Thomas; Singh, Raveena; McKinnell, James A.; Miller, Loren G.; Huang, Susan S.
• Is Part Of: Infection control and hospital epidemiology. Volume 42:Number 12(2021)
• Page Start: 1493
• Page End: 1496
• Publication Date: 2021-12-16
• Subjects: Nosocomial infections -- Epidemiology -- Periodicals; Health facilities -- Sanitation -- Periodicals; Hospital buildings -- Sanitation -- Periodicals; Cross Infection -- Periodicals; Epidemiology -- Periodicals; Hospitals -- Periodicals; Infection Control -- Periodicals; 614.44
• DOI: 10.1017/ice.2020.1412
• Languages: English
• ISSNs: 0899-823X

Abstract

ABSTRACT: We performed secondary analyses of a postdischarge decolonization trial of MRSA carriers that reduced MRSA infection and hospitalization by 30%. Hospitalized MRSA infection was associated with 7.9 days of non-MRSA antibiotics and CDI in 3.9%. Preventing MRSA infection and associated hospitalization may reduce antibiotic use and CDI incidence.